This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase III

  • Nasal Glucagon hypoglycemia
    Nasal glucagon is a biologic entity being studied for the treatment of severe hypoglycemia in people with diabetes treated with insulin.

    For more information on nasal glucagon clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-7/19/2016)

     

     
  • Empagliflozin
    BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for type 1 diabetes.

    For more information on BI10773 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-7/19/2016)

    None during this time period.

     

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase II

  • Ultra Rapid Insulin
    URI is pursued pre-FRD through two approaches, BioChaperone insulin lispro in collaboration with Adocia and an internal ultra-rapid formulation project of insulin lispro. Both projects are biologic entities being studied for the treatment of type 1 and type 2 diabetes.

    For more information on BioChaperone Lispro clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • diabetes
    New chemical entity. Molecule is owned by a 3rd party, Lilly retains rights.

     
  • DGAT-2 inhibitor dyslipidemia
    "DGAT-2 inhibitor" is a new chemical entity being studied for the treatment of dyslipidemia.

     
  • GIP/GLP-1 Co-agonist Peptide
    "GIP/GLP-1 Co-agonist Peptide" is a new biologic entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic